NCT02462239|CompletedDMC
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
PET MUSE
Loading search results
PET MUSE
Sponsor study identifier
interventional
292
1 country
6
Study Start
May 6, 2016
Actual (reported)Primary Completion
March 31, 2024
Actual (reported)Study Completion
November 14, 2024
Actual (reported)Bladder cancer is the fifth most common cancer in Canada and there has been relatively little progress in altering its clinical course over the last three decades. One of the major problems identified in the management of this disease, is under staging of muscle invasive disease which can lead to suboptimal treatment and outcomes. PET-CT has the potential to more accurately stage MIBC than standard CT by detecting pelvic adenopathy and/or distant sites of disease that may not be found on standard imaging. In the former situation, more aggressive therapy with extended lymph node dissection and/or neoadjuvant chemotherapy prior to cystectomy can be offered. While in the latter situation patients can be spared the morbidity of a cystectomy performed in a setting of metastatic disease. This study will address whether PET-CT adds a clinically meaningful difference in care.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 14, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 27, 2015
Actual (reported)June 4, 2015
Actual (reported)May 6, 2016
Actual (reported)March 31, 2024
Actual (reported)November 14, 2024
Actual (reported)Treatment received
For patients with planned cystectomy, treatment received includes: avoidance of planned cystectomy and node dissection, an extended (vs standard) node dissection (or standard dissection when extended is the surgeon's usual practice), use of neoadjuvant chemotherapy (vs no neoadjuvant chemotherapy). For patients with planned bladder conservation, treatment received includes: avoidance of bladder and nodal radiation (vs bladder only or no radiation) and use of neoadjuvant chemotherapy (or not).
5 years
Disease-free survival
5 years
Overall survival
5 years
Quality of life analysis
5 years
Health economic analysis
5 years
Change in planned management
5 years
Clinical and pathology response to chemotherapy using interim response of FDG PET-CT after 2 cycles of chemotherapy
5 years
Whole-body FDG PET-CT (Experimental arm)
No PET-CT (Control arm)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
London Regional Cancer Centre
London, Ontario, N6A 4L6, Canada
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, P7B 6V4, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Srikala Sridhar, MD
Princess Margaret Hospital, Canada
Nicholas Power, MD
LHSC-Victoria Hospital
Som Mukherjee, MD
Juravinski Cancer Centre
Ur Metser, MD
Princess Margaret Hospital, Canada
292 participants (actual enrollment reported by the registry).
First Submitted
May 27, 2015
First Posted
June 4, 2015
Study Start
May 6, 2016
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
March 31, 2024
Actual (reported)Study Completion
November 14, 2024
Actual (reported)Last Updated
November 22, 2024
Record last verified: 2024-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: